Phosphatidylcholine-Cannabinoid Complex for Addiction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for addiction are ineffective in addressing the underlying biochemical imbalances in cell membranes, particularly the ratio of sphingomyelin to phosphatidylcholine, which contributes to the progression of addiction-related symptoms and health issues.
Innovation Solution
A cannabinoid-based combination therapy comprising a balanced PC composition, including phosphatidylcholine, phosphatidylethanolamine, and essential fatty acids, administered with cannabinoids to regulate cell membrane biochemistry and reduce the sphingomyelin to phosphatidylcholine ratio, enhancing bioavailability and therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cannabinoid therapy is administered alone, then therapeutic effects are achieved, but bioavailability is limited and side effects increase
Solution Approach 1:
Phosphatidylcholine serves as a mediator that enhances cannabinoid delivery to the central nervous system. The phosphatidylcholine-cannabinoid complex facilitates better penetration of the blood-brain barrier, improving therapeutic efficacy while reducing the required dosage and associated side effects.
Solution Approach 2:
The invention creates a composite therapeutic composition combining phosphatidylcholine with cannabinoids. This composite approach leverages the membrane-transport properties of phosphatidylcholine to enhance cannabinoid delivery, achieving synergistic effects that improve reliability while minimizing harmful factors.
2Ease of operation
If conventional addiction treatments are used, then some symptomatic relief is provided, but underlying biochemical imbalances in cell membranes are not addressed
Solution Approach 1:
The phosphatidylcholine component prepares and optimizes cell membrane conditions before cannabinoid action occurs. By pre-establishing proper membrane fluidity and receptor availability, the treatment enhances subsequent cannabinoid efficacy in addressing addiction while maintaining operational simplicity.
Data Source
AI summary
This invention relates to compositions containing combinations of a balanced PC composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of using such combinations to treat subjects suffering from addiction to substances and related diseases or disorders. This invention also relates to the synergistic effect of such combination therapies in humans.